<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Guillain-Barré syndrome in children: Treatment and prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Guillain-Barré syndrome in children: Treatment and prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Guillain-Barré syndrome in children: Treatment and prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eppie Yiu, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas R Nordli, Jr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Adrienne G Randolph, MD, MSc
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The acute immune-mediated polyneuropathies are classified under the eponym Guillain-Barré syndrome (GBS) after some of the authors of early descriptions of the disease. GBS is one of the most common causes of acute, acquired weakness and is often provoked by a preceding infection. GBS may be complicated in some cases by respiratory failure and autonomic dysfunction.
        </p>
        <p>
         The management and prognosis of GBS in children will be reviewed here.
        </p>
        <p>
         Other aspects of GBS in children are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6235.html" rel="external">
          "Guillain-Barré syndrome in children: Epidemiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
         GBS in adults is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5137.html" rel="external">
          "Guillain-Barré syndrome in adults: Pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5172.html" rel="external">
          "Guillain-Barré syndrome in adults: Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          MONITORING AND SUPPORTIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         During the initial phase of GBS, all patients require close monitoring of motor, autonomic (ie, blood pressure, heart rate, and sphincter function), and respiratory function. Serial pulmonary function testing should be performed routinely. In most cases, pulmonary function monitoring (ie, vital capacity and maximum inspiratory pressure) should be performed every four hours at the bedside. All children, particularly those who are too young to cooperate with pulmonary testing, should be closely monitored and observed for fatigue and other clinical signs of impending respiratory muscle failure, as discussed below.
        </p>
        <p>
         Patients should be electively intubated if clinical evaluation or pulmonary function tests suggest impending respiratory failure. Vigilance is essential since respiratory deterioration can occur rapidly. (See
         <a class="local">
          'Ventilatory status'
         </a>
         below.)
        </p>
        <p>
         Mortality is often due to complications such as nosocomial infection, acute respiratory arrest, deep venous thrombosis with pulmonary embolism, and pneumothorax. Outcomes can be optimized with meticulous care in the intensive care unit to identify patients progressing to respiratory failure early and to prevent hospital-acquired complications.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Indication for ICU level of care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with any of the following problems should be admitted urgently to a pediatric intensive care unit (ICU) [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flaccid quadriparesis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapidly progressive weakness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced vital capacity (≤20 mL/kg)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bulbar palsy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant autonomic instability
        </p>
        <p>
        </p>
        <p>
         Less severely affected patients can be managed in intermediate care units if available, and mildly affected patients whose trajectory is stable can be managed on the general ward, preferably with cardiac telemetry, along with monitoring of blood pressure and vital capacity every four hours. Hospitalization is continued until the child's condition has clearly stabilized.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Ventilatory status
         </span>
         <span class="headingEndMark">
          —
         </span>
         Up to 20 percent of children with GBS require mechanical ventilation for respiratory failure [
         <a href="#rid3">
          3-5
         </a>
         ]. The need for tracheal intubation should be anticipated so that it can be performed as an elective procedure [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Risk factors for respiratory failure include [
         <a href="#rid5">
          5,7,8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Shorter time from onset of neurologic symptoms to admission
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cranial nerve involvement
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autonomic dysfunction
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.criteria.blood.gov.au%2FNeurologicalScales%23GBS&amp;token=F2fTJXWTbAdqtiUVhUGfEXKWxuI01ZlYZcU5Lj8XZKN10U7%2FSG9BJDEspjv1Gev6TP1yMPF5FjvzjL9XCWfuug%3D%3D&amp;TOPIC_ID=6204" target="_blank">
          GBS disability score
         </a>
         at admission
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher CSF protein level
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Axonal forms of GBS
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older age
        </p>
        <p>
        </p>
        <p>
         The Erasmus GBS Respiratory Insufficiency Scale for children (EGRIS-Kids) is a prognostic model designed to predict risk of respiratory failure in children with GBS [
         <a href="#rid5">
          5
         </a>
         ]. The scale assigns points for age (0 for ≤5 years, 1 for 6 to 10 years, 2 for &gt;10 years),
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.criteria.blood.gov.au%2FNeurologicalScales%23GBS&amp;token=F2fTJXWTbAdqtiUVhUGfEXKWxuI01ZlYZcU5Lj8XZKN10U7%2FSG9BJDEspjv1Gev6TP1yMPF5FjvzjL9XCWfuug%3D%3D&amp;TOPIC_ID=6204" target="_blank">
          GBS disability scale
         </a>
         score at admission (1 to 4 for nonintubated scores in scale), and cranial nerve involvement (0 for absence, 3 for presence). The scale is scored from 1 to 9; results correlate with the risk of respiratory failure ranging from 4 to 50 percent.
        </p>
        <p>
         Children with a vital capacity approximately one-half the normal value for age or ≤20 mL/kg of body weight generally progress to require ventilatory support. In one study of patients with GBS that included some children, serial measurements of pulmonary function were most helpful for detecting the risk of developing respiratory failure [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         The following parameters warn of impending respiratory arrest and are an indication for urgent intubation [
         <a href="#rid9">
          9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vital capacity ≤20 mL/kg
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maximum inspiratory pressure less negative than -30 centimeters of water (cmH
         <sub>
          2
         </sub>
         O; ie, between -30 and 0 cmH
         <sub>
          2
         </sub>
         O)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maximum expiratory pressure ≤40 cmH
         <sub>
          2
         </sub>
         O
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tidal volume &lt;5 mL/kg
        </p>
        <p>
        </p>
        <p>
         Pulmonary function testing is difficult in children who cannot cooperate, typically those younger than six years of age. These patients should be closely monitored and observed for fatigue and other clinical signs of impending respiratory muscle failure. These signs include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A sustained increase in partial pressure of carbon dioxide (pCO
         <sub>
          2
         </sub>
         ) to ≥50 mmHg (normally 35 to 40 mmHg)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An increasing respiratory rate
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increasing oxygen requirement and increasing alveolar to arterial oxygen difference (normally 5 to 10 mmHg)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An increased use of accessory muscles (eg, sternocleidomastoid use, flaring of the alae nasi, intercostal retractions) and decreased or paradoxical diaphragm movements; these reflect decreased chest wall movement and low lung volumes
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sweating about the head and neck, wide pulse pressure, and bounding pulses; these portend respiratory failure with carbon dioxide (CO
         <sub>
          2
         </sub>
         ) retention
        </p>
        <p>
        </p>
        <p>
         Children have less metabolic and muscle reserve than adults. They can deteriorate quite rapidly and suddenly become apneic or develop alveolar hypoventilation. Generally, it is wise to have a pediatric critical care specialist involved early in the clinical course.
        </p>
        <p>
         Sedation and neuromuscular blockade should be avoided where possible in ventilated patients because they obscure the course of the illness. Scrupulous airway care and chest physiotherapy reduce the risk of pneumonia. Tracheostomy may be needed if prolonged ventilation is required.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Autonomic status
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autonomic dysfunction is a well-recognized feature of GBS and is a significant source of mortality [
         <a href="#rid6">
          6,10
         </a>
         ]. Consequently, close monitoring of blood pressure, fluid status, and cardiac rhythm are essential to the management of these patients. Care must also be taken when vasoactive or sedative drugs are used, because GBS-related dysautonomia may exaggerate the hypotensive responses to these drugs.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Other supportive measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nutritional needs should be addressed early in the disease course. Orogastric tube feeding, gastrostomy, or parenteral nutrition is often necessary.
        </p>
        <p>
         The patient's position should be changed frequently for comfort and to avoid skin breakdown. Intermittent-pressure leg boots are used in the intensive care setting to prevent deep vein thrombosis.
        </p>
        <p>
         Pain is prominent and distressing for many children with GBS and their families. Early recognition and treatment of neuropathic pain is important to facilitate comfort and participation in physical therapy [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6254.html" rel="external">
          "Pain in children: Approach to pain assessment and overview of management principles"
         </a>
         .)
        </p>
        <p>
         Physical therapy, occupational therapy, and social services should be involved early. Providing the patient with a method of communication is important if normal speech is not possible. Pencil and paper or a communication board can be given to those old enough to write.
        </p>
        <p class="headingAnchor" id="H89027759">
         <span class="h1">
          IMMUNOTHERAPIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The main modalities of therapy for GBS are intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         (IVIG) and plasma exchange (also called plasmapheresis). While acknowledging the limitations of data for children, we suggest treatment with IVIG or plasma exchange for children with severe GBS, in general agreement with guidelines from the American Academy of Neurology (AAN) and other consensus statements [
         <a href="#rid2">
          2,11-13
         </a>
         ].
        </p>
        <p>
         Glucocorticoids are not beneficial for GBS and have no role in its treatment [
         <a href="#rid14">
          14-16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1095594768">
         <span class="h2">
          Indications for treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         and plasma exchange for children with GBS should be reserved for those with any of the following indications [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Progressing weakness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Worsening respiratory status or need for mechanical ventilation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant bulbar weakness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inability to walk unaided
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         and plasma exchange are not recommended for children with mild symptoms who are unlikely to benefit from these therapies, including those who are ambulatory, who have mild, nonprogressive disease, or for children whose mild symptoms have stabilized. Children who have rapid progression followed by stabilization of symptoms within the first or second week of GBS onset may still be considered candidates for treatment by some child neurologists.
        </p>
        <p>
         Time to treatment onset may be important in children although data are lacking. In general,
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         is recommended for patients who are unable to walk unaided if treatment is started within two or possibly four weeks of onset. Similarly, plasma exchange is recommended for patients who are unable to walk unaided if treatment is started within four weeks of symptom onset [
         <a href="#rid12">
          12,17,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3340564096">
         <span class="h2">
          Selection of agent
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         is preferred to plasma exchange in children because of the relative safety and ease of administration, although there are no high-quality data to suggest that one is superior to the other. In a randomized trial from Egypt that enrolled 41 children with very severe GBS necessitating ventilatory support, there was no significant difference between treatment with plasma exchange versus IVIG for length of stay in the pediatric intensive care unit or for ability to walk unaided at four weeks after discharge [
         <a href="#rid19">
          19
         </a>
         ]. However, the duration of mechanical ventilation was significantly shorter for the group treated with plasma exchange (median 11 days, versus 13 days for IVIG). This finding requires confirmation in larger, more rigorous trials. In adults, IVIG and plasma exchange are equally effective [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5172.html" rel="external">
          "Guillain-Barré syndrome in adults: Treatment and prognosis", section on 'Selection of agent'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Intravenous immune globulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reports of the use of
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         in children with GBS are limited, and no large randomized controlled trials exist. Nevertheless, data from the available small open-label randomized trials in children suggest that IVIG shortens the time to recovery compared with supportive care alone [
         <a href="#rid17">
          17,20,21
         </a>
         ]. Similarly, most observational studies show that IVIG hastens recovery in children [
         <a href="#rid22">
          22-26
         </a>
         ]. While these trials and studies in children have not proven that IVIG leads to improvement in overall prognosis, their results are consistent with the larger randomized trials showing a beneficial effect of IVIG treatment for GBS in adults. (See
         <a class="medical medical_review" href="/z/d/html/5172.html" rel="external">
          "Guillain-Barré syndrome in adults: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
         The mechanism of improvement with
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         is uncertain, but it is thought to involve suppression of inflammatory and immune-mediated processes. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy", section on 'Suppression of inflammatory/autoimmune processes'
         </a>
         .)
        </p>
        <p>
         Methodologic differences between reports make it difficult to generalize about when children with GBS begin to improve after
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         treatment. Nevertheless, muscle strength generally begins to improve in most children within 14 days after initiation of IVIG therapy and most are walking within three months [
         <a href="#rid24">
          24-26
         </a>
         ]. Early transient relapse (or "treatment-related fluctuations") after IVIG treatment has been reported [
         <a href="#rid21">
          21,27-29
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – The total dose of
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         for the treatment of GBS in children is 2 g/kg, given as 1 g/kg for two days or 400 mg/kg for five days. This dose is empiric and is based upon treatment of patients with immune deficiency disorders. The dosage schedule is also empiric as little is known of the pharmacokinetics of serum immunoglobulin G (IgG) [
         <a href="#rid30">
          30
         </a>
         ]. Many centers give a total of 2 g/kg of IVIG over two days, however one small trial suggested a slightly greater risk of treatment-related fluctuations with this regimen as opposed to a five-day course [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Typically, patients are given only a single course of
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         treatment. There is very little evidence to support an additional course of IVIG in severe cases of GBS or in patients showing no recovery within two weeks of presentation. A randomized, placebo-controlled trial in adults with GBS who had a predicted poor prognosis not only failed to show benefit from a second course of IVIG, but also showed increased rates of serious adverse events with repeat treatment [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with a treatment-related fluctuation (defined as disease progression occurring within two months following an initial treatment-induced clinical improvement or stabilization) however, may respond to a second course of
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         , although evidence for this is limited [
         <a href="#rid2">
          2,18,32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Complications and side effects of
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         treatment are those related to transfusion reactions and are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7947.html" rel="external">
          "Immunologic transfusion reactions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Plasma exchange
         </span>
         <span class="headingEndMark">
          —
         </span>
         Large multicenter trials have established the effectiveness of plasma exchange in adult patients with severe GBS. The mechanism is thought to be removal of antibodies directed against nerves from the circulation. Increased muscle strength, earlier neurologic improvement, and a less frequent need for mechanical ventilation have been demonstrated, as discussed separately.
        </p>
        <p>
         In an meta-analysis of six trials and 649 patients with GBS that included a small number of children who were all ≥10 years of age, treatment with plasma exchange was superior to supportive care [
         <a href="#rid18">
          18
         </a>
         ]. Plasma exchange was most effective when started within seven days of symptom onset but may still be beneficial if started within four weeks of initial symptoms. Compared with supportive care, patients treated with plasma exchange had a slightly higher risk of relapse in the first year after treatment but nevertheless were more likely at one year to have full recovery of muscle strength.
        </p>
        <p>
         In general, results of plasma exchange in pediatric patients appear to be similar to those in adults, with a shortened disease course and reduced incidence of respiratory failure. The main benefit seems to be a decrease in the interval from maximum weakness to recovery of independent walking [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         As a result of the cost, risk, and discomfort to the patient, plasma exchange generally is not used in very young children, for ambulatory patients with mild disease, or for patients whose symptoms have stabilized.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Procedure
         </strong>
         – Plasma exchange requires special equipment and trained personnel and can be performed only at centers with expertise in the treatment of children. Because of technical considerations, this procedure is more challenging in children younger than two years of age. The procedure usually consists of four to six double-volume exchanges performed on alternate days over one week. Immunoglobulin levels may be decreased by 30 to 40 percent after plasma exchange.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – The frequency and types of complications from therapeutic apheresis depend on the overall condition of the patient, the number of plasma exchanges, the replacement fluid, and the venous access device. For all therapeutic apheresis, patients may be at risk for citrate-induced hypocalcemia, metabolic alkalosis, or complications related to the vascular catheter. Potential early symptoms of hypocalcemia include perioral and distal extremity paresthesias or numbness; severe reactions can include tetany, prolongation of the QT interval, arrhythmias, or hypotension. (See
         <a class="medical medical_review" href="/z/d/html/7942.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Complications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Younger children most often require placement of a central venous catheter. Potential complications of central venous catheters include infection, pain, nerve damage, thrombosis, perforation, dissecting hematomas, air embolism, or arteriovenous fistulas. Many of these complications can also occur if peripheral veins are used.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H89027132">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, the prognosis of GBS in children is better than in adults [
         <a href="#rid7">
          7,34-37
         </a>
         ]. In various reports, the following observations were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mortality is generally less than 2 to 3 percent in most pediatric GBS cohorts [
         <a href="#rid5">
          5,38-40
         </a>
         ]. However mortality rates are higher in resource-limited settings [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Approximately 90 percent of children were ambulatory within six months after onset, and nearly all (96 percent) walk within one year [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An excellent long-term recovery (eg, symptom-free or no disability despite residual symptoms) was observed in 85 to 92 percent of children [
         <a href="#rid15">
          15,42,43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 52 children with a median follow-up of 11 years, sequelae of GBS were reported by 65 percent of patients; the most common residual complaints were paresthesia, unsteady gait in the dark, painful hands or feet, and severe fatigue. Long-term neurologic deficits included sensory loss, limb weakness, and areflexia in 14, 8, and 5 percent, respectively [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment-related fluctuations occur in up to 7 percent of cases of childhood GBS and are generally responsive to immunomodulatory treatment [
         <a href="#rid34">
          34
         </a>
         ]. Approximately 2 percent of children go on to have recurrent weakness and are ultimately diagnosed with chronic inflammatory demyelinating polyneuropathy [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5264.html" rel="external">
          "Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrence of GBS was reported in 2 to 5 percent [
         <a href="#rid34">
          34,43
         </a>
         ], which can occur months to years after the initial episode.
        </p>
        <p>
        </p>
        <p>
         Although most children with GBS experience excellent recovery, outcomes may be less favorable in the following groups [
         <a href="#rid7">
          7,39,40,44-48
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Very young age (&lt;2 years)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe weakness at presentation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid progression of weakness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cranial nerve involvement
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Require ventilator support
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Have inexcitable motor nerves on nerve conduction studies
        </p>
        <p>
        </p>
        <p>
         The long-term outcome of GBS does not appear to differ substantially among the GBS subtypes [
         <a href="#rid43">
          43,47,49,50
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/6235.html" rel="external">
          "Guillain-Barré syndrome in children: Epidemiology, clinical features, and diagnosis", section on 'Variant forms of Guillain-Barré syndrome'
         </a>
         ). In an observational study of Japanese children with GBS, outcomes were generally favorable in both acute inflammatory demyelinating polyneuropathy (AIDP) and acute motor axonal neuropathy (AMAN) subtypes, although delayed recovery was more frequent with AMAN [
         <a href="#rid49">
          49
         </a>
         ]. All 11 children with AIDP and 12 of 15 (80 percent) with AMAN regained the ability to walk independently at six months; 14 of 15 children (93 percent) with AMAN walked independently at two years. Differences in clinical recovery between children with AIDP and AMAN were not statistically significant.
        </p>
        <p class="headingAnchor" id="H1550413204">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114912.html" rel="external">
          "Society guideline links: Guillain-Barré syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H89027908">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supportive care
         </strong>
         – All patients with Guillain-Barré syndrome (GBS) require close monitoring of motor, autonomic (ie, blood pressure, heart rate, and sphincter function), and respiratory function during the acute phase of the illness. (See
         <a class="local">
          'Monitoring and supportive care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Indication for ICU level of care
         </strong>
         – Children with GBS who have flaccid quadriparesis, rapidly progressive weakness, reduced vital capacity (≤20 mL/kg), bulbar palsy, or autonomic instability should be admitted emergently to a pediatric intensive care unit. (See
         <a class="local">
          'Indication for ICU level of care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ventilatory status
         </strong>
         – Vital capacity and maximum inspiratory pressure should be assessed every four hours at the bedside. All children, particularly those too young to cooperate with pulmonary testing, should be closely monitored and observed for fatigue and other clinical signs of impending respiratory muscle failure. (See
         <a class="local">
          'Ventilatory status'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Clinical signs of impending respiratory muscle failure include a sustained increase of partial pressure of carbon dioxide (
         <sub>
          p
         </sub>
         CO
         <sub>
          2
         </sub>
         ) to ≥50 mmHg, increasing respiratory rate, an increased use of accessory muscles and decreased or paradoxical diaphragm movements, sweating about the head and neck, wide pulse pressure, and bounding pulses.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Parameters that warn of impending respiratory arrest and are an indication for elective intubation include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Vital capacity ≤20 mL/kg
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Maximum inspiratory pressure less negative than -30 centimeters of water (cmH
         <sub>
          2
         </sub>
         O; ie, between -30 and 0 cmH
         <sub>
          2
         </sub>
         O)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Maximum expiratory pressure ≤40 cmH
         <sub>
          2
         </sub>
         O
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Tidal volume &lt;5 mL/kg
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Autonomic dysfunction
         </strong>
         – Autonomic dysfunction is a well-recognized feature of GBS and is a significant source of mortality. Therefore, management requires close monitoring of blood pressure, fluid status, and cardiac rhythm. (See
         <a class="local">
          'Autonomic status'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunotherapies
         </strong>
         – We suggest treatment with intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         (IVIG) or plasma exchange for children with severe GBS (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ), as defined by the presence of one or more of the following characteristics (see
         <a class="local">
          'Immunotherapies'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Progressing weakness
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Worsening respiratory status or need for mechanical ventilation
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Significant bulbar weakness
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Inability to walk unaided
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We prefer
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         to plasma exchange for the treatment of children because of its relative safety and ease of administration, although it has not been shown to have better results. Neither treatment is recommended for ambulatory children with GBS who have mild disease or for children whose symptoms have stabilized. However, children who have rapid progression followed by stabilization of symptoms within the first or second week of GBS onset may still be considered candidates for treatment. (See
         <a class="local">
          'Immunotherapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Data regarding the prognosis of GBS in children suggest a mortality rate of up to 2 to 3 percent and an excellent long-term recovery (eg, symptom-free or no disability despite residual symptoms) in 90 percent or more of children. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4166253625">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Robert P Cruse, DO, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Agrawal S, Peake D, Whitehouse WP. Management of children with Guillain-Barré syndrome. Arch Dis Child Educ Pract Ed 2007; 92:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol 2019; 15:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu MH, Chen CM, Lin KL, et al. Risk factors of respiratory failure in children with Guillain-Barré syndrome. Pediatr Neonatol 2012; 53:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo H, Hong S, Li M, et al. Risk factors for mechanical ventilation in children with Guillain-Barré syndrome. Muscle Nerve 2020; 62:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roodbol J, Korinthenberg R, Venema E, et al. Predicting respiratory failure and outcome in pediatric Guillain-Barré syndrome. Eur J Paediatr Neurol 2023; 44:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes RA, Wijdicks EF, Benson E, et al. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 2005; 62:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Estrade S, Guiomard C, Fabry V, et al. Prognostic factors for the sequelae and severity of Guillain-Barré syndrome in children. Muscle Nerve 2019; 60:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rantala H, Uhari M, Cherry JD, Shields WD. Risk factors of respiratory failure in children with Guillain-Barré syndrome. Pediatr Neurol 1995; 13:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 2001; 58:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hund EF, Borel CO, Cornblath DR, et al. Intensive management and treatment of severe Guillain-Barré syndrome. Crit Care Med 1993; 21:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korinthenberg R, Trollmann R, Felderhoff-Müser U, et al. Diagnosis and treatment of Guillain-Barré Syndrome in childhood and adolescence: An evidence- and consensus-based guideline. Eur J Paediatr Neurol 2020; 25:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes RA, Wijdicks EF, Barohn R, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003; 61:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012; 78:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes RA. Ineffectiveness of high-dose intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1991; 338:1142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korinthenberg R, Mönting JS. Natural history and treatment effects in Guillain-Barré syndrome: a multicentre study. Arch Dis Child 1996; 74:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2016; 10:CD001446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014; :CD002063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev 2017; 2:CD001798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Bayoumi MA, El-Refaey AM, Abdelkader AM, et al. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study. Crit Care 2011; 15:R164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gürses N, Uysal S, Cetinkaya F, et al. Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome. Scand J Infect Dis 1995; 27:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 2005; 116:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanra G, Ozon A, Vajsar J, et al. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Eur J Paediatr Neurol 1997; 1:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahar E, Shorer Z, Roifman CM, et al. Immune globulins are effective in severe pediatric Guillain-Barré syndrome. Pediatr Neurol 1997; 16:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singhi SC, Jayshree M, Singhi P, et al. Intravenous immunoglobulin in very severe childhood Guillain-Barré syndrome. Ann Trop Paediatr 1999; 19:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shahar E, Leiderman M. Outcome of severe Guillain-Barré syndrome in children: comparison between untreated cases versus gamma-globulin therapy. Clin Neuropharmacol 2003; 26:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yata J, Nihei K, Ohya T, et al. High-dose immunoglobulin therapy for Guillain-Barré syndrome in Japanese children. Pediatr Int 2003; 45:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irani DN, Cornblath DR, Chaudhry V, et al. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993; 43:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castro LH, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology 1993; 43:1034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koul R, Chacko A, Ahmed R, et al. Ten-year prospective study (clinical spectrum) of childhood Guillain-Barré syndrome in the Arabian peninsula: comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras. J Child Neurol 2003; 18:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 2009; 66:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walgaard C, Jacobs BC, Lingsma HF, et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 2021; 20:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruts L, Drenthen J, Jacobs BC, et al. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 2010; 74:1680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein MA, Sladky JT. The role of plasmapheresis in childhood Guillain-Barré syndrome. Ann Neurol 1990; 28:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study. Neuropediatrics 2007; 38:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones HR. Childhood Guillain-Barré syndrome: clinical presentation, diagnosis, and therapy. J Child Neurol 1996; 11:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delanoe C, Sebire G, Landrieu P, et al. Acute inflammatory demyelinating polyradiculopathy in children: clinical and electrodiagnostic studies. Ann Neurol 1998; 44:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hung PL, Chang WN, Huang LT, et al. A clinical and electrophysiologic survey of childhood Guillain-Barré syndrome. Pediatr Neurol 2004; 30:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans OB, Vedanarayanan V. Guillain-Barré syndrome. Pediatr Rev 1997; 18:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barzegar M, Toopchizadeh V, Maher MHK, et al. Predictive factors for achieving independent walking in children with Guillain-Barre syndrome. Pediatr Res 2017; 82:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalita J, Kumar M, Misra UK. Prospective comparison of acute motor axonal neuropathy and acute inflammatory demyelinating polyradiculoneuropathy in 140 children with Guillain-Barré syndrome in India. Muscle Nerve 2018; 57:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shibeshi MS, Mengesha AA, Gari KT. Pediatric Guillain-Barré Syndrome in a Resource Limited Setting: Clinical Features, Diagnostic and Management Challenges, and Hospital Outcome. Pediatric Health Med Ther 2023; 14:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asbury AK. New concepts of Guillain-Barré syndrome. J Child Neurol 2000; 15:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roodbol J, de Wit MC, Aarsen FK, et al. Long-term outcome of Guillain-Barré syndrome in children. J Peripher Nerv Syst 2014; 19:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cole GF, Matthew DJ. Prognosis in severe Guillain-Barré syndrome. Arch Dis Child 1987; 62:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vajsar J, Fehlings D, Stephens D. Long-term outcome in children with Guillain-Barré syndrome. J Pediatr 2003; 142:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin JJ, Hsia SH, Wang HS, et al. Clinical variants of Guillain-Barré syndrome in children. Pediatr Neurol 2012; 47:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karalok ZS, Taskin BD, Yanginlar ZB, et al. Guillain-Barré syndrome in children: subtypes and outcome. Childs Nerv Syst 2018; 34:2291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devi AK, Randhawa MS, Bansal A, et al. Long-Term Neurological, Behavioral, Functional, Quality of Life, and School Performance Outcomes in Children With Guillain-Barré Syndrome Admitted to PICU. Pediatr Neurol 2023; 140:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagasawa K, Kuwabara S, Misawa S, et al. Electrophysiological subtypes and prognosis of childhood Guillain-Barré syndrome in Japan. Muscle Nerve 2006; 33:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tekgul H, Serdaroglu G, Tutuncuoglu S. Outcome of axonal and demyelinating forms of Guillain-Barré syndrome in children. Pediatr Neurol 2003; 28:295.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6204 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18032711" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Management of children with Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31541214" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Diagnosis and management of Guillain-Barrésyndrome in ten steps.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23084721" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Risk factors of respiratory failure in children with Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32367533" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Risk factors for mechanical ventilation in children with Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36931152" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Predicting respiratory failure and outcome in pediatric Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16087757" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Supportive care for patients with Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31531862" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Prognostic factors for the sequelae and severity of Guillain-Barrésyndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8771163" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Risk factors of respiratory failure in children with Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11405803" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Anticipating mechanical ventilation in Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8440115" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Intensive management and treatment of severe Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31941581" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Diagnosis and treatment of Guillain-BarréSyndrome in childhood and adolescence: An evidence- and consensus-based guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14504313" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Practice parameter: immunotherapy for Guillain-Barrésyndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22454268" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1682558" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Ineffectiveness of high-dose intravenous methylprednisolone in Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8669925" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Natural history and treatment effects in Guillain-Barrésyndrome: a multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27775812" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Corticosteroids for Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25238327" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Intravenous immunoglobulin for Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28241090" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Plasma exchange for Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21745374" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barrésyndrome: a randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8539548" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15995024" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barrésyndrome: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10728186" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Intravenous immunoglobulin treatment in children with Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9044398" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Immune globulins are effective in severe pediatric Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10690257" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Intravenous immunoglobulin in very severe childhood Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12671527" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Outcome of severe Guillain-Barrésyndrome in children: comparison between untreated cases versus gamma-globulin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14521529" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : High-dose immunoglobulin therapy for Guillain-Barrésyndrome in Japanese children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8492939" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Relapse in Guillain-Barrésyndrome after treatment with human immune globulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8492921" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Human immune globulin infusion in Guillain-Barrésyndrome: worsening during and after treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14696904" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Ten-year prospective study (clinical spectrum) of childhood Guillain-Barrésyndrome in the Arabian peninsula: comparison of outcome in patients in the pre- and post-intravenous immunoglobulin eras.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19938102" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33743237" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Second intravenous immunoglobulin dose in patients with Guillain-Barrésyndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20427754" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2375635" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The role of plasmapheresis in childhood Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17607598" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinical presentation and course of childhood Guillain-Barrésyndrome: a prospective multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8745378" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Childhood Guillain-Barrésyndrome: clinical presentation, diagnosis, and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9749601" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Acute inflammatory demyelinating polyradiculopathy in children: clinical and electrodiagnostic studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14984898" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A clinical and electrophysiologic survey of childhood Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8993064" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28422939" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Predictive factors for achieving independent walking in children with Guillain-Barre syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29053890" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prospective comparison of acute motor axonal neuropathy and acute inflammatory demyelinating polyradiculoneuropathy in 140 children with Guillain-Barrésyndrome in India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36993874" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Pediatric Guillain-BarréSyndrome in a Resource Limited Setting: Clinical Features, Diagnostic and Management Challenges, and Hospital Outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10757475" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : New concepts of Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24863162" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Long-term outcome of Guillain-Barrésyndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3566320" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Prognosis in severe Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12640380" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Long-term outcome in children with Guillain-Barrésyndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22759683" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Clinical variants of Guillain-Barrésyndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29948140" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Guillain-Barrésyndrome in children: subtypes and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36587490" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Long-Term Neurological, Behavioral, Functional, Quality of Life, and School Performance Outcomes in Children With Guillain-BarréSyndrome Admitted to PICU.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16506153" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Electrophysiological subtypes and prognosis of childhood Guillain-Barrésyndrome in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12849884" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Outcome of axonal and demyelinating forms of Guillain-Barrésyndrome in children.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
